Clinical trial NCT00200954: Primary Prevention of Atopic Disease by Perinatal Administration of Probiotics
Official title: Primary Prevention of Atopic Disease by Perinatal Administration of Probiotics.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Food Allergy
Atopic Dermatitis
Asthma
Rhinitis
Keywords: prospective
intervention
randomised
probiotics
atopy
Lead sponsor: The Netherlands Asthma Foundation
Sponsor class: OTHER
Collaborators: name: UMC Utrecht
First posted: 2005-09-20
Enrollment: 157
Sex: ALL
Minimum age (years): 20
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Administration of probiotics to pregnant women from an atopic family and subsequently to their high-risk newborns results in prevention of the incidence or in a decrease of the severity of atopic disease during infancy.

Detailed description: Background. Atopic diseases are increasing in countries with a Western lifestyle. The hygiene hypothesis states that the increase in atopic disease could be due to reduced exposure to microbial antigens in early in life. In search of new preventive therapies for atopic disease, exposure of pregnant women with previous or recent atopic disease, and their offspring to probiotics has been suggested. Probiotics are mono or mixed cultures of microbes which, when applied to animal or man, can beneficially affect the host, among others by inducing an immune response. Probiotics are generally accepted to be safe in children. Probiotics have shown to be effective in primary prevention of atopic disease in high-risk neonates in one study so far. However, it is still unclear by what mechanism probiotics work and which is the most immunopotent (combinations of) probiotic(s). It is likely that antigen-presenting cells (APC's) are involved, since these cells are important in the first line of defence in the gastrointestinal tract. It can be imagined that the immune response is the result of the interplay between probiotics and APC's. In particular, the match between pathogen-associated molecular patterns (PAMP's) on probiotics and their counterparts on APC's, the pathogen-recognition-receptors (PRR's) (like for instance Toll-like receptors) is decisive in this aspect.

Hypothesis. Administration of probiotics to pregnant women and their offspring may reduce the development of sensitization as well as the onset of atopic disease in their offspring.

Aim. To study the effect of probiotics on sensitisation and the prevalence of atopic disease, the severity of atopic disease, the intestinal flora and immune parameters in high-risk newborns.

Methods. To study this hypothesis, a randomised, double-blind placebo-controlled trial will be carried out by administration of probiotics to pregnant women with previous or recent atopic disease as well as to their offspring. Primary outcome parameters are firstly the prevalence and severity of sensitization and atopic disease in the offspring during a follow-up of two years. Secondary outcome parameters are the change in stool composition during treatment with probiotics and in-vitro production of cytokines by PBMCs collected at 3 months, 1 year and 2 years of age.

Expected results. Perinatal administration of probiotics to pregnant women and their offspring may hamper the development of sensitization and atopic disease in their offspring. This may be due to modulation of the intestinal microbiota composition, and modulation of the developing immune system

Eligibility criteria: Inclusion Criteria:

* Pregnant mothers were included if either they themselves or their husband plus one sibling suffered from present or past atopic disease

Exclusion Criteria:

* Maternal use of immunomodulatory drugs during pregnancy, the use of probiotics prior to the start of the study.
* Children were excluded from the study if their mother received antibiotic treatment during the last two weeks of pregnancy
* When the child was born preterm, i.e. before 37 weeks of gestation
* If the children received antibiotic treatment in the first two weeks of life
* If ingestion of the study product was difficult due to vomiting or feeding problems in general for longer than 3 weeks from birth
* If the children had other major medical problems

Primary outcomes:
measure: Incidence and severity of atopic disease at the age of 2 years. Incidence and prevalence of eczema
timeFrame: Follow-up at 3 months, 12 months, and 24 months
Secondary outcomes:
measure: Serum IgE, stool composition, cytokines produced by PBMNC's
timeFrame: Follow-up at 3 months, 12 months and 24 months
Other outcomes:
Locations:
city: Utrecht
country: Netherlands
facility: Wilhelmina Children's Hospital (UMCU)
Study officials:
affiliation: Wilhelmina Children's Hospital Utrecht (UMCU)
name: Maarten O Hoekstra, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: